Mizuho Lowers Price Target for Haemonetics Corporation Amid Sector Review
Mizuho analyst Anthony Petrone reduced the price target for Haemonetics Corporation (HAE) from $80 to $70 while maintaining an Outperform rating as part of a sector-wide review ahead of first-quarter earnings. The adjustment reflects broader lowered estimates across medical devices and diagnostics companies. Additionally, HAE received FDA approval for an expanded use of its VASCADE MVP XL venous closure system.
Tickers: $HAE
Topics: FDA approval medical devices price target change stock analysis